Owlet is the Utah, NYSE-listed maker of the smart sock, whose Dream Sock became an FDA-cleared over-the-counter infant monitor.

Owlet brings the round its wearable node — the Utah company that defined the smart sock, weathered an FDA warning over its original device, and returned with a Dream Sock cleared as an over-the-counter infant monitor. Its answer to a round about who owns the monitor and where it is made is a public, wearable one: a NYSE-listed US company whose story is inseparable from the regulator.

Its identity is the cleared smart sock. The wearable sock, the FDA-clearance journey and the strict limits on what it may claim are the story here. A sock, cleared. The cleared smart sock.

(Honest notes, so the FDA saga is bounded and the claim limits are absolute. Owlet sells wearable infant monitoring as its heroes — the Dream Sock, a wearable foot sensor reporting pulse rate and blood-oxygen and sold over the counter, the prescription BabySat sibling, and Dream and Cam cameras; we report its language as the brand’s own. On the FDA saga, dated where documented and hedged where not: Owlet received an FDA warning letter in 2021 that its original Smart Sock was being marketed as an unapproved, uncleared medical device because it reported heart rate and oxygen, and Owlet stopped US sales of the original Smart Sock in late 2021 and pivoted to a Dream Sock sold as a sleep-wellness product; the exact warning-letter date we treat as to-be-verified. Later, and documented on Owlet’s own site, the Dream Sock became the first FDA-cleared over-the-counter infant monitoring device, a Class II device cleared via the De Novo pathway, reporting pulse rate and blood-oxygen and clinically validated across skin tones, with BabySat as the prescription version; the exact clearance dates, around 2023, we treat as to-be-verified. On the absolute limits, mirroring Owlet’s own copy: cleared for vitals is not the same as preventing sudden infant death syndrome — Owlet itself disclaims diagnosing, treating or preventing SIDS, and we never imply it prevents SIDS or is life-saving; we never present the original Smart Sock as cleared, since it was the subject of the warning letter; and cleared is not the same as approved. As regulatory backdrop, in September 2025 the FDA cautioned families about unauthorised infant monitors that claim to track vital signs without review, which is exactly why the cleared-versus-wellness distinction matters. On origin: Owlet is American, based in Lehi, Utah, founded in 2012, and publicly traded as OWLT. Its designs, the Owlet, Dream Sock and BabySat names are IP we describe but do not reproduce; there is no official brand hex; these tones are an unofficial interpretation.)

Owlet lives in an owl teal. Click a swatch to copy the hex.

Owlet’s identity is reassuring, wearable and cleared — an owl teal, an ink, a pale sea, a deep pine, and a paper. The palette leans owl teal and pale sea: a calm, reassuring register that nods to a wearable infant monitor rather than a loud logo colour. It signals the cleared smart sock — reassuring, wearable and cleared. The honest caveat: with no official brand hex, these values are an original, unofficial interpretation, not first-party colours.

The lesson is an owl teal signals a reassuring, wearable identity. Owlet’s world is a sock that reads a baby’s pulse and oxygen. For designers, it is a reminder that a calm teal and a soft sea can carry a wearable baby-tech brand — a reassuring tone held as an accent, not a product shot. Because a mid hue can fail as small text, keep type dark and let the colour live in the accents, palette and band. The takeaways: date the FDA saga carefully and hedge the exact dates; say Dream Sock is FDA-cleared (not approved) for vitals, never for SIDS; never present the original Smart Sock as cleared; and keep the SIDS and life-saving claims off entirely.

The register is a wearable sans — reassuring, wearable, cleared.

Owlet’s identity carries a reassuring, wearable, cleared spirit — a category-defining wearable, not a plain camera. A wearable sans captures the mood: clean, calm and modern, the register of a reassuring device worn by a baby. Set in an owl-teal palette, the wearable sans feels reassuring and wearable — exactly the personality Owlet carries. It behaves like a made, careful thing rather than a loud logo, mirroring a soft-glow arc and a breathing-wave ring. (Owlet’s real products and the Dream Sock and BabySat names are things we describe but do not reproduce, and the exact typeface is not ours to use.) Because it is not ours to use, the honest description is “a wearable-sans brand,” shown here in a stand-in. The type behaves like the brand: reassuring, wearable and cleared.

Owlet stands for the cleared smart sock.

Owlet brings the round its wearable node. An owl-teal palette, a wearable sans and a 2012 founding make one thing — the cleared smart sock — the whole identity: reassuring, wearable and cleared. The wearable sock is the pitch, and the FDA-clearance journey is the story. The point is a public US company whose device is defined by the regulator, in a round about who owns the monitor and where it is made.

Put to work, the identity is the brand told straight, the saga dated and the claim limits absolute. A brand in this spirit would date the FDA saga carefully, say Dream Sock is FDA-cleared for vitals but never for SIDS, and never present the original Smart Sock as cleared. A reader in this spirit would keep the facts right: Owlet sells the Dream Sock and prescription BabySat as heroes; it is American, based in Lehi, Utah, founded in 2012, listed as OWLT; its original Smart Sock drew a 2021 FDA warning letter and was pulled from US sale; its Dream Sock is now the first FDA-cleared over-the-counter infant monitor, a Class II De Novo device for pulse and oxygen; and it does not prevent SIDS. Owlet sits second in the round, after Nanit. The honest editorial moves are to date the saga, to say cleared not approved and for vitals not SIDS, to never call the original sock cleared, and to keep the SIDS claims off.

For designers and brand-builders, Owlet continues the baby monitor: tell a regulatory journey precisely — and hold the claim limits absolutely. The lessons: a brand can be defined by its path through the FDA, from a warning letter to a De Novo clearance; the difference between cleared and approved, and between cleared-for-vitals and SIDS-prevention, is stated exactly; an earlier product that was the subject of a warning is never presented as cleared; and the September 2025 FDA caution about unauthorised infant monitors is the backdrop that makes the distinction matter. It is also a reminder to stay precise: Owlet is the Utah, NYSE-listed maker of the smart sock, whose Dream Sock became an FDA-cleared over-the-counter infant monitor — with the palette here an unofficial interpretation. The hook is that journey: Owlet’s original sock drew an FDA warning, and the company came back with a Dream Sock cleared for pulse and oxygen over the counter — a real regulatory milestone that still, by Owlet’s own words, does not prevent SIDS. Read that way, Owlet is less a simple sock than the cleared smart sock: reassuring, wearable, cleared. The lesson for a brand is that a regulatory story and absolute claim discipline reinforce each other, and never overreaching on SIDS keeps the story earned. Owlet made the-cleared-smart-sock the identity — proof that a regulatory journey can carry a round.

Keep Owlet’s identity on hand — save it to a board in the Made Good inspiration library.